News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RedHill Biopharma Ltd. Announces a Successful Pivotal Bioequivalence Trial with RHB-102 for the Prevention of Nausea and Vomiting in Cancer Patients


4/18/2012 10:00:29 AM

TEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd. (TASE: RDHL), an emerging Israeli biopharmaceutical company focusing primarily on development of late clinical-stage (Phase II/III), new formulations and combinations of existing drugs, announces positive results in an advanced bioequivalence clinical trial with RHB-102 for the prevention of nausea and vomiting in cancer patients. RedHill intends to approach the FDA in the coming weeks to request a Pre-NDA meeting to discuss US marketing approval pathway.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES